SETH LEDERMAN - 27 Feb 2024 Form 4 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Role
Chief Executive Officer, Director
Signature
/s/ Seth Lederman
Issuer symbol
TNXP
Transactions as of
27 Feb 2024
Transactions value $
$0
Form type
4
Filing time
29 Feb 2024, 17:08:09 UTC
Previous filing
24 Feb 2023
Next filing
27 Feb 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNXP Stock Option Award $0 +235,320 $0 235,320 27 Feb 2024 Common Stock 235,320 $0.368 Direct F1, F2
transaction TNXP Stock Option Award $0 +1,903,680 $0 1,903,680 27 Feb 2024 Common Stock 1,903,680 $0.46 Direct F1, F2
transaction TNXP Stock Option Award $0 +1,309,911 $0 1,309,911 27 Feb 2024 Common Stock 1,309,911 $0.0368 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 One-third of the option vests on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
F2 The option was granted pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan.